CGEN-15092

Status: Target Validation

CGEN-15092 is a novel B7/CD28-like immune checkpoint target candidate discovered by Compugen.

CGEN-15092 Fc fusion protein was shown to inhibit activation of T cells and to modulate the immune system in-vivo, as demonstrated in the EAE model of multiple sclerosis.